menu ☰
menu ˟

No increase for pancreatitis, pancreatic cancer with incretin therapy in type 2 diabetes

20 Nov 2018
Second-line incretin therapies, including DPP-IV inhibitors and GLP-1 receptor agonists, do not increase the risk for pancreatitis or pancreatic cancer when added to metformin in type 2 diabetes, according to findings published in Diabetic Medicine....

Click here to view the full article which appeared in Endocrinology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.